贝舒地尔(Belumosudil Mesilate) - 药物靶点：ROCK1 x ROCK2_在研适应症：慢性移植物抗宿主病，同种异体移植排斥反应，肺移植排斥反应_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Belumosudil Mesylate、甲磺酸贝舒地尔、BN-101

+ [11]

靶点

ROCK1 x ROCK2

作用机制

ROCK1抑制剂(Rho相关蛋白激酶-1抑制剂)、ROCK2抑制剂(Rho相关蛋白激酶-2抑制剂)

治疗领域

免疫系统疾病其他疾病感染+ [4]

在研适应症

慢性移植物抗宿主病同种异体移植排斥反应肺移植排斥反应+ [3]

非在研适应症

自身免疫性疾病纤维化特发性肺纤维化+ [3]

原研机构

Kadmon Pharmaceuticals LLC

在研机构

Kadmon Pharmaceuticals LLC

National Heart, Lung & Blood Institute

Sanofi

+ [8]

非在研机构

Kadmon Corp. LLCKadmon Holdings, Inc.

最高研发阶段批准上市

首次获批日期

美国 (2021-07-16),

慢性移植物抗宿主病

最高研发阶段(中国)批准上市

特殊审评优先审评 (美国)、突破性疗法 (美国)、孤儿药 (美国)、突破性疗法 (中国)、孤儿药 (韩国)、孤儿药 (澳大利亚)、优先审评 (澳大利亚)

登录后查看时间轴

结构/序列

分子式C27H28N6O5S

InChIKeyILQJXEIRBCHLOM-UHFFFAOYSA-N

CAS号2109704-99-4

关联

42

项与贝舒地尔相关的临床试验

NCT05567406

/ Recruiting临床2期

A Phase 2, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Participants With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy

The purpose of this study is to measure safety and efficacy of oral belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander male and female participants with cGVHD who have previously been treated with at least 2 prior lines of systemic therapy aged 12 years and above.
The duration of participants participation will be up to 4 weeks for screening, treatment until clinically significant progression of disease, and 4 weeks of safety follow-up, and then long-term follow-up every 12 weeks.1 Cycle = 28 days.

开始日期2025-01-31

申办/合作机构

Kadmon Holdings, Inc.

NCT06476132

/ Not yet recruiting临床2期IIT

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients: A Randomized, Multicenter, Double Blind, Placebo-Controlled Trial (CTOT-47)

The purpose of this study is to see if taking the study drug, Belumosudil, for 52 weeks in addition to your usual care and medication, will prevent Chronic Lung Allograft Dysfunction (CLAD) in participants who have a lung biopsy that shows evidence of rejection or inflammation to the transplanted lung(s). For this study, biopsies that show evidence of Acute Rejection (AR), Lymphocytic Bronchiolitis (LB), Organizing Pneumonia (OP) or Acute Lung Injury (ALI) are referred to as "Qualifying Biopsies"; patients who had evidence of one or more of these conditions on a recent biopsy are eligible for enrollment in this study. Belumosudil is an investigational drug that blocks a molecule in the body that reduces inflammation and scarring and may play a role in the development and progression of CLAD. Belumosudil is a drug approved by the FDA to treat adults and children 12 years and older with chronic graft-versus-host disease (cGVHD), a condition with some similarities to CLAD.
The primary objective it to determine the efficacy of treatment with Belumosudil + maintenance immunosuppression (IS) versus placebo + maintenance IS on preventing the subsequent development of probable or definite CLAD, lung retransplant, or death.

开始日期2025-01-21

申办/合作机构

National Institute of Allergy & Infectious Diseases

NCT06751602

/ Not yet recruiting临床2期IIT

A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Belumosudil for the Abrogation of Interstitial Fibrosis and Tubular Atrophy in De Novo Kidney Transplant Recipients

This is a randomized, double-blind, placebo-controlled trial in de novo kidney transplant patients to determine if the addition of belumosudil (brand name- REZUROCK®) on the background of standard immunosuppression will prevent fibrosis in the kidney transplant. Interstitial expansion is the precursor of interstitial fibrosis and graft loss. We hypothesize that abgrogating the fibrogenic effects of the RhoA pathway with belumosudil will reduce structural damage in transplanted kidneys and possible subsequent transplant failure.

开始日期2025-01-15

申办/合作机构

The Methodist Hospital Research Institute

100 项与贝舒地尔相关的临床结果

登录后查看更多信息

100 项与贝舒地尔相关的转化医学

登录后查看更多信息

100 项与贝舒地尔相关的专利（医药）

登录后查看更多信息

104

项与贝舒地尔相关的文献（医药）

2025-01-02·LEUKEMIA & LYMPHOMA

Combination ruxolitinib and belumosudil is tolerable and induces responses despite treatment failure as monotherapies

Article

作者: Bhatta, Subodh ; Larkin, Karilyn ; Mims, Alice ; Brammer, Jonathan ; Choe, Hannah ; Peddireddi, Ayush ; Caputo, Jean ; Wall, Sarah ; Vasu, Sumithira ; Bezerra, Evandro ; Huang, Ying

FDA approved agents for the treatment of chronic GVHD including ruxolitinib and belumosudil are effective steroid-sparing agents, with overall response rates (ORR) of 76% and 65% respectively. Ruxolitinib and belumosudil are well tolerated with different primary targets. Little data is available on the use of combination ruxolitinib and belumosudil. This is a single center, retrospective analysis of 20 treatment-refractory patients with chronic GVHD treated with combination ruxolitinib and belumosudil. The ORR including complete response (CR) and partial response (PR) at any time was 55% (11/20). Among responding patients, other immunosuppressive agents were tapered or discontinued in all patients. None of the patients developed EBV or CMV reactivation requiring treatment. 4 patients (20%) developed pneumonia and 2 patients (10%) developed viral URI. Cytopenias were not exacerbated. No patients had graft failure or relapsed disease. The combination is tolerable, delays the need for alternative therapies, and facilitates tapering of corticosteroids.

2024-12-01·Current Hematologic Malignancy Reports

Contemporary Updates in the Prevention and Treatment of Graft-Versus-Host Disease

Review

作者: Abedin, Sameem ; Hamadani, Mehdi

PURPOSE OF REVIEW:

Graft-versus-host disease (GVHD) is a serious complication after allogeneic HCT. Recently, several pivotal studies have been conducted demonstrating significant improvements in the management of GVHD. Here, we review important trials pertaining to GVHD prevention, acute GVHD treatment, and treatment of steroid refractory acute and chronic GVHD.

RECENT FINDINGS:

Clinical trials in preventing GVHD demonstrate lower rates of severe acute GVHD and chronic GVHD with post-transplant cyclophosphamide. For acute GVHD, lower risk acute GVHD appears amenable to steroid-sparing therapies, such as sirolimus and itacitinib. Combinations with novel agents such as itolizumab appear promising for high risk acute GVHD. For steroid-refractory acute GVHD, ruxolitinib should be considered first line therapy. For chronic GVHD requiring therapy beyond steroids, ruxolitinib, belumosudil, and ibrutinib are now available and should be considered. Increasingly, GVHD has become a manageable complication after allogeneic HCT potentially translating to greater success with allogeneic HCT in the future.

2024-10-01·BIOORGANIC CHEMISTRY

Discovery of novel pyrazolo[1,5-a]pyrimidine derivatives as selective ROCK2 inhibitors with anti-breast cancer migration and invasion activities

Article

作者: Yue, Lingfeng ; Jiang, Nan ; Zhai, Xin ; Zhang, Jiahe ; Cao, Zhi ; Wei, Xiujian ; Zhang, Jiahao ; Xing, Shuming ; Wang, Shuqi

Rho-associated coiled-coil kinase (ROCK) is involved in multiple cellular activities regulating the actin cytoskeleton, such as cell morphology, adhesion, and migration. The inhibition of ROCK is a feasible strategy to suppress breast cancer metastasis. Herein, based on Belumosudil, a series of pyrazolo[1,5-a]pyrimidine derivatives as selective ROCK2 inhibitors were designed and synthesized. Through systematic investigation of SARs, the piperazine analog 7u was identified with optimum ROCK2 inhibitory activity (IC₅₀ = 36.8 nM) and excellent selectivity over the isoform protein ROCK1 (>250-fold). Intriguingly, upon treatment with 7u, the arrangement of the MDA-MB-231 cytoskeleton was affected accompanied by the alteration of morphology. Furthermore, cell scratch and transwell assays indicated that 7u inhibited MDA-MB-231 cell migration and invasion in a dose-dependent manner. Ultimately, the binding model of 7u with ROCK2 well accounted for the superior activities of 7u as a promising ROCK2 inhibitor with the potential application in breast cancer metastasis treatment.

100

项与贝舒地尔相关的新闻（医药）

2025-01-08

·医药魔方

医保落地创新药大年，“全球新”慢性排异创新药创新在哪里？

1月1日，《国家基本医疗保险、工伤保险和生育保险药品目录（2024年）》（以下简称“新版医保目录”）正式实施。本次新版医保目录纳入的91种新药中有38种为“全球新”创新药物。其中，全球首个且唯一获批用于12岁及以上糖皮质激素治疗应答不充分的慢性移植物抗宿主病（cGVHD）患者的ROCK2抑制剂[1,2]甲磺酸贝舒地尔片随着新版医保目录落地正惠及全国患者。短短一周的时间湖北、浙江、江苏、上海、广东、山东、北京、天津、重庆、吉林等省市地区患者已相继用上了医保落地后的创新药物，这也展现了当下中国移植术后并发症管理市场对于创新疗法日益增长的需求。慢性移植物抗宿主病俗称“慢性排异”，2023年，我国共完成异基因造血干细胞移植（allo-HSCT）14,952例[3]，为全球第一，成为名副其实的“移植大国”。随着allo-HSCT覆盖恶性血液病如急性髓系白血病（AML）、急性淋巴细胞白血病（ALL）、慢性髓性白血病（CML）、多发性骨髓瘤（MM）等人数增加，以及非恶性血液病，如重型再生障碍性贫血（SAA）、地中海贫血等更多应用，这一数字将不断攀升。然而30%-70%异基因造血干细胞移植患者术后都存在发生cGVHD的风险[4]。“慢性排异”这一常见的并发症正成为移植后的“次生灾害”，更需要针对性的创新药物。国家医保局于12月9日举办了2024年国家医保药品目录解读活动，重点列举了9个具有代表性的品种。这些产品临床价值大、创新程度高、价格合理、填补空白，其中包括cGVHD ROCK2抑制剂甲磺酸贝舒地尔片[5]。早筛早诊早治准则下，cGVHD“一线困境”亟需二线创新 “慢性排异”，会累及皮肤、眼睛、口腔、关节等多个组织器官，严重影响患者生活质量，更是异基因造血干细胞移植患者晚期非复发性死亡的首要原因[6]。在“早筛早诊早治”的cGVHD管理“黄金准则”下，这一情况可以有效预防与避免。但目前的困境是许多cGVHD患者在术后管理中更多聚焦于移植的原发病，往往容易忽视并发症症状。而cGVHD等移植后并发症的早期，症状多样且不典型，容易漏诊误诊。同时在治疗层面，超过一半的cGVHD患者在接受一线标准治疗后，仍需二线或更后线的治疗[7]，患者对于更具有针对性的创新疗法存在巨大的需求。现有二线治疗有甲氨蝶呤、吗替麦考酚酯等，近年来也出现JAK抑制剂、BTK抑制剂、ROCK2抑制剂等治疗药物。不同药物的作用机制不同，大部分药物均聚焦于抑制免疫炎症，无法有效抑制纤维化，往往无法直击根源控制疾病进展。在治疗过程中纤维化是核心难点。目前cGVHD的治疗目标一方面需要建立免疫耐受以维持免疫稳态，进而有效预防、减少纤维化，另一方面对于发生纤维化的组织和器官，希望能够有效的逆转纤维化，因此免疫稳态和逆转纤维化是cGVHD的治疗目标的核心，选择针对性治疗方式尤为关键。随着更多创新疗法，如ROCK2抑制剂甲磺酸贝舒地尔的出现，cGVHD的治疗也步入“双管齐下”的时代，即恢复免疫平衡并逆转纤维化的双向机制，为临床尽早达成治疗目标与cGVHD规范化管理提供有力武器。实现维持免疫稳态的价值还在于能够治疗cGVHD同时可保留移植物抗白血病（GVL）效应。GVL效应帮助减少白血病的复发，但也可能导致GVHD，也就是说维持免疫稳态有助于减少GVHD和白血病复发间两头受困的情况。从二线冲击一线，ROCK2抑制剂还有更多“后手” 在cGVHD一线治疗困境下，ROCK2抑制剂正在寻找突破口。今年5月，甲磺酸贝舒地尔的一线III期临床试验获得NMPA批准，成为cGVHD首个纳入中国人群的全球多中心III期临床研究。随着研究的进展，ROCK2抑制剂正向一线疗法发起冲刺，更好满足患者的未尽之需。同时，甲磺酸贝舒地尔片用于治疗成人双肺移植后慢性移植肺功能丧失（CLAD）的全球多中心III期临床研究正在同步推进中。随着研究的深入，其有望从血液移植向实体器官移植进一步探索，成为CLAD的创新“破局者”。随着甲磺酸贝舒地尔片医保落地，在中国惠及更多患者。而ROCK2抑制剂的研发潜力之下，更多不同类型的患者还将从中获益，踏入移植术后并发症管理的全新的时代！ - 上下滑动查看参考资料 - [1]中国甲磺酸贝舒地尔片说明书，审批日期2023年8月。 [2] Kurian, Tony J., and Frederick Locke. The Hematologist 18.6 (2021). [3]中华医学会血液学分会造血干细胞应用学组.造血干细胞移植登记2023.1.1-2023.12.31[R].中华医学会血液学分会,2023:2. [4]中华医学会血液学分会造血干细胞应用学组,中国抗癌协会血液病转化委员会.慢性移植物抗宿主病(cGVHD)诊断与治疗中国专家共识(2021年版)[J].中华血液学杂志, 2021, 42(4):11.DOI:10.3760/cma.j.issn.0253-2727.2021.04.001. [5]https://m.peopledailyhealth.com/trailerDetial?contentId=fba08215db6948a19ea82b243fc62306 [6] Cooke KR et al. Biol Blood Marrow Transplant. 2017;23(2):211-234. doi:10.1016/j.bbmt.2016.09.023 [7] Cutler, C., et al., Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood, 2021. 138(22): 2278-2289. Copyright © 2025 PHARMCUBE. All Rights Reserved. 欢迎转发分享及合理引用，引用时请在显要位置标明文章来源；如需转载，请给微信公众号后台留言或发送消息，并注明公众号名称及ID。免责申明：本微信文章中的信息仅供一般参考之用，不可直接作为决策内容，医药魔方不对任何主体因使用本文内容而导致的任何损失承担责任。

申请上市

2025-01-01

·赛诺菲中国

新版医保目录落地，慢性排异“全球新”创新药易来克®惠及全国患者

点击赛诺菲中国关注我们向上滑动了解更多关于赛诺菲中国赛诺菲是一家全球领先的创新医药健康企业，以“追寻科学奇迹，焕发生命光彩”为使命。作为改革开放后首批进入中国的跨国企业之一，赛诺菲1982年便在中国建立了办公室，目前拥有12处多元模式的办公室，3家生产基地和4大研发基地，多元化业务覆盖制药、人用疫苗和消费者保健。赛诺菲与中国同心同行，致力于将创新药品和疫苗加速引进中国，不断变革医疗实践，造福更多中国百姓，也为合作伙伴、社区和员工创造更美好的生活。如需了解更多信息，请访问www.sanofi.cn ，或关注“赛诺菲中国”微信公众号。关于赛诺菲赛诺菲是一家全球领先的创新医药健康企业。我们的使命是追寻科学奇迹，焕发生命光彩。赛诺菲的足迹遍及全球100多个国家，致力于变革医疗实践，将不可能变为可能。我们为世界各地的人们提供潜在改变生活的医疗健康解决方案以及预防可致命疾病的疫苗，同时将可持续和社会责任置于我们雄伟战略的核心。

疫苗

2024-12-25

·Business Wire

Meiji Seika Pharma: Announcement of the Establishment of Local Subsidiary "Taiwan Meiji Pharma Co., Ltd." in Taiwan

TOKYO--( BUSINESS WIRE )--Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo, President: Daikichiro Kobayashi) announced the establishment of a local subsidiary, "Taiwan Meiji Pharma Co., Ltd." (Headquarters: Taipei City, Taiwan, Chairman: Kenshi Murase), on December 18 th . This subsidiary will focus on pharmaceutical sales and other related activities in Taiwan and is scheduled to commence operations in February 2025. 1. Purpose and Background of Establishment Meiji Seika Pharma aims to become "a leading company in Asia in the field of infectious diseases" as part of the "Meiji Group 2026 Vision" targeting the year 2026. By establishing Taiwan Meiji Pharma Co., Ltd. in Taiwan, the fifth largest pharmaceutical market in Asia, we aim to build a business foundation and achieve further growth by supplying products. Taiwan Meiji Pharma Co., Ltd. plans to launch "REZUROCK" (product name in Japan, generic name: belumosudil mesylate), a selective ROCK2 inhibitor for the treatment of chronic graft-versus-host disease (Chronic GVHD), which is currently under application for regulatory approval with the Taiwan Food and Drug Administration (TFDA). Chronic GVHD is a disease that occurs following hematopoietic stem cell transplantation performed for the treatment of leukemia. We will also consider the continuous introduction of other products such as antibiotics and vaccines. 2. Company Overview (1) Name: Taiwan Meiji Pharma Co., Ltd. (2) Location: 14F, No.51 Section2 Keelung Rd. Xinyi District, Taipei city, 110502, Taiwan (R.O.C) (3) Representative (Chairman): Kenshi Murase (4) Business Description: Sales of pharmaceutical medicines, etc. (5) Capital: 30 million New Taiwan Dollars (6) Date of Establishment: December 18 th , 2024 (7) Shareholder Composition: Wholly owned subsidiary with 100% investment by Meiji Seika Pharma Co., Ltd. Through Taiwan Meiji Pharma Co., Ltd., Meiji Seika Pharma will stably supply products needed by patients and contribute to the health of the people in Taiwan.

上市批准申请上市

100 项与贝舒地尔相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11815 D11816	-	-	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
慢性移植物抗宿主病	美国	Kadmon Pharmaceuticals LLC	2021-07-16

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
同种异体移植排斥反应	临床3期	美国	Sanofi	2023-10-10
同种异体移植排斥反应	临床3期	中国	Sanofi	2023-10-10
同种异体移植排斥反应	临床3期	澳大利亚	Sanofi	2023-10-10
同种异体移植排斥反应	临床3期	奥地利	Sanofi	2023-10-10
同种异体移植排斥反应	临床3期	比利时	Sanofi	2023-10-10
同种异体移植排斥反应	临床3期	加拿大	Sanofi	2023-10-10
同种异体移植排斥反应	临床3期	捷克	Sanofi	2023-10-10
同种异体移植排斥反应	临床3期	丹麦	Sanofi	2023-10-10
同种异体移植排斥反应	临床3期	芬兰	Sanofi	2023-10-10
同种异体移植排斥反应	临床3期	法国	Sanofi	2023-10-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03640481 (KD025-213 \| ROCKstar Study \| ROCKstar, CTgov)	临床2期	慢性移植物抗宿主病	159	Belumosudil (KD025) (Adolescent Arm A: Belumosudil 200 mg QD)	鏇範窪廠蓋膚艱窪壓簾(醖憲廠製鹽築膚築繭鬱) = 獵膚鏇壓獵鏇獵鬱襯觸糧膚鬱範鹹簾顧糧衊鏇 (簾鏇選壓願廠製繭鬱築, 艱衊蓋積願築網艱構鹹 ~ 壓積鹽夢鬱鬱網獵蓋選) 更多	-	2024-12-12
NCT03640481 (KD025-213 \| ROCKstar Study \| ROCKstar, CTgov)	临床2期	慢性移植物抗宿主病	159	Belumosudil (KD025) (Adolescent Arm B: Belumosudil 200 mg BID)	鏇範窪廠蓋膚艱窪壓簾(醖憲廠製鹽築膚築繭鬱) = 衊齋艱簾網壓衊積淵廠糧膚鬱範鹹簾顧糧衊鏇 (簾鏇選壓願廠製繭鬱築, 範壓鹹衊淵鹹遞築鏇衊 ~ 衊積餘醖窪憲窪觸襯衊) 更多	-	2024-12-12
ASH2024	N/A	慢性移植物抗宿主病	-	Belumosudil	繭簾構鏇構網獵鏇鏇積(鹽夢廠鬱廠觸廠淵蓋淵) = 衊衊鬱願獵構壓糧艱衊繭廠廠鑰選獵願鹹憲餘 (襯繭繭鏇糧鬱醖壓衊餘 ) 更多	-	2024-12-08
KD-025-2134 (EHA2024) 人工标引	N/A	类固醇难治性移植物抗宿主病	45	Belumosudil	築衊鑰網壓淵範選廠範(範廠夢範艱簾網願鹽願) = 壓鹽窪願積襯壓醖積繭鬱顧製製鹽鏇憲範糧簾 (蓋獵繭築襯獵衊膚廠醖 ) 更多	积极	2024-05-14
EHA 12024 \| EHA 22024 人工标引	临床3期	慢性移植物抗宿主病	21	Belumosudil 200 mg	糧遞糧積蓋蓋壓廠獵廠(廠觸衊醖顧艱窪製蓋獵) = 廠壓選糧顧遞積糧鏇鑰構襯獵鏇襯廠獵糧鹹顧 (願顧遞衊餘願艱壓衊顧, 63.66 ~ 96.95) 更多	积极	2024-05-14
EHA2024	N/A	移植物抗宿主病	35	Belumosudil	遞襯獵鏇襯選齋選夢壓(願夢廠範蓋糧積糧築鑰) = 2 patients where additional treatment for cGvHD had to be initiated 廠憲夢齋獵鏇鹽築鏇膚 (廠願壓觸積網鏇窪製艱 ) 更多	积极	2024-05-14
NCT04930562 (Pubmed) 人工标引	临床2期	慢性移植物抗宿主病二线	30	Belumosudil 200 mg	糧鏇顧齋構憲顧蓋遞襯(憲繭淵鏇鏇廠簾襯壓顧) = 窪觸壓網醖範憲鑰鹹襯鬱鹹醖簾鑰鹹構醖鏇憲 (網鬱顧鹹窪鹹鏇鏇鹽鏇, 54.1 ~ 87.7) 更多	积极	2024-03-26
NCT03640481 (ROCKstar, Tandem Meetings ASTCT and CIBMTR2024) 人工标引	临床2期	移植物抗宿主病末线 \| 三线	152	Belumosudil 200 mg QD	膚廠鹽繭壓遞衊衊鏇鬱(鹽製鹹壓蓋衊膚觸襯壓) = 夢簾淵遞簾襯鏇襯選膚衊鹽簾築願鑰範選憲遞 (遞積廠選範鏇淵網網糧 ) 更多	积极	2024-02-01
	临床2期	移植物抗宿主病末线 \| 三线	152	Belumosudil 200 mg BID	膚廠鹽繭壓遞衊衊鏇鬱(鹽製鹹壓蓋衊膚觸襯壓) = 鹽膚鬱夢齋網範夢觸築衊鹽簾築願鑰範選憲遞 (遞積廠選範鏇淵網網糧 ) 更多	积极	2024-02-01
Tandem Meetings ASTCT and CIBMTR2024 人工标引	N/A	类固醇难治性移植物抗宿主病	66	Belumosudil	衊網鏇糧艱鏇鏇遞襯糧(鑰糧淵壓憲壓獵網憲衊) = 膚構鹹壓獵繭窪範築製獵顧衊糧壓構鬱襯餘憲 (淵夢艱製窪簾鹽壓顧窪, 70 ~ 90) 更多	积极	2024-02-01
Tandem Meetings ASTCT and CIBMTR2024 人工标引	N/A	类固醇难治性移植物抗宿主病	14	Belumosudil-Ruxolitinib (bel-rux) dual therapy	糧齋遞糧簾襯壓廠觸窪(製襯積鏇鑰積範構繭蓋) = 範壓壓繭獵範遞糧鹹壓醖鬱觸積製網鬱選鹽遞 (獵餘艱鑰顧選觸壓築鬱 ) 更多	积极	2024-02-01
NCT04930562 (phase II study of belumosudil, CTgov)	临床2期	慢性移植物抗宿主病	30	BN101	顧顧壓鬱齋糧顧願淵齋(築顧鹽壓糧顧鹹餘製繭) = 夢膚製網鹹夢積範蓋製壓襯鑰範積遞觸積憲憲 (窪窪築醖壓鏇醖鹽願鑰, 顧積觸餘襯願廠壓範蓋 ~ 網襯鏇艱願選夢製蓋簾) 更多	-	2023-11-01